Last reviewed · How we verify
BMS-986231
BMS-986231 is an anti-PD-1 monoclonal antibody.
BMS-986231 is an anti-PD-1 monoclonal antibody. Used for Non-small cell lung cancer, Melanoma.
At a glance
| Generic name | BMS-986231 |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BMS-986231 works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby enhancing T cell activation and anti-tumor activity.
Approved indications
- Non-small cell lung cancer
- Melanoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
- An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic (PHASE2)
- Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure (PHASE2)
- An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function (PHASE1)
- A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function (PHASE2)
- A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants (PHASE1)
- A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function (PHASE1)
- A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure (PHASE2)
- Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |